Equities research analysts at Goldman Sachs Group assumed coverage on shares of Solid Biosciences (NASDAQ:SLDB) in a research report issued to clients and investors on Tuesday, February 20th, Marketbeat Ratings reports. The brokerage set a “neutral” rating and a $31.00 price target on the stock. Goldman Sachs Group’s price objective suggests a potential upside of 17.83% from the stock’s current price.
Solid Biosciences (NASDAQ SLDB) traded down $0.13 during mid-day trading on Tuesday, hitting $26.31. The company had a trading volume of 290,903 shares, compared to its average volume of 194,602. The company has a market capitalization of $898.51 and a P/E ratio of -28.91. Solid Biosciences has a 12-month low of $19.12 and a 12-month high of $33.74.
In other news, Director Life Sciences Maste Perceptive bought 1,020,000 shares of Solid Biosciences stock in a transaction on Tuesday, January 30th. The stock was acquired at an average cost of $16.22 per share, for a total transaction of $16,544,400.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.
TRADEMARK VIOLATION NOTICE: This news story was originally reported by The Lincolnian Online and is owned by of The Lincolnian Online. If you are viewing this news story on another domain, it was copied illegally and republished in violation of US and international trademark & copyright laws. The legal version of this news story can be viewed at https://www.thelincolnianonline.com/2018/03/14/solid-biosciences-sldb-receives-new-coverage-from-analysts-at-goldman-sachs-group.html.
About Solid Biosciences
Solid Biosciences Inc, formerly Solid Biosciences, LLC, is a life science company. The Company is focused on developing therapies for duchenne muscular dystrophy (DMD). It is developing gene therapies, disease modifying therapies and assistive devices, all targeting the various facets of the DMD. Its corrective therapies platform is engaged in the development of gene therapy candidates for DMD.
Receive News & Ratings for Solid Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Solid Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.